Neurosense Therapeutics is trading at $4.18, up 6.23% on October 5; no catalyst was identified.
- On October 2, the company said it had failed Nasdaq’s $35 million minimum market-value requirement by September 29, following a prolonged share-price decline, and plans to appeal and seek more time to regain compliance.
- Shares are expected to continue trading while the appeal is pending. The company also said it regained compliance with Nasdaq’s $1.00 minimum-bid-price rule.
- No separate October 5 announcement was found; broad indices were mixed.